The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody alone, according to the results of a Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators. These findings are likely to change the recommendations for treatment of indolent forms of lymphoma.
Treating Cancer Patients Amid the Pandemic
April 24, 2020
A diagnosis of cancer is one of the most frightening things a patient could ever receive . Despite great advances made in treatment, early detection, and prevention, patients will often feel vulnerable and lost in a maze of the unknown. And now, in the face of the ongoing coronavirus pandemic, every one of us — the healthy and those with health ailments — also feels vulnerable.
Macaulay Students to Assist With COVID-19 Effort
April 10, 2020
Interns in the Englander Institute for Precision Medicine at Weill Cornell Medicine/RLab internship program will work on a tool to identify areas in the US where COVID-19 symptoms are emerging.
Macaulay Honors College today announced a plan for student interns in the college’s RLab program to be redeployed to assist in a national COVID-19 monitoring effort.
EIPM Launches Weekly News Roundup!
April 10, 2020
During normal times it can be difficult to find reliable and accurate news about health, medicine and science. But during a global pandemic, when information can directly affect our lives and our work, this challenge takes on far greater significance.
April 2020 EIPM Director’s Memo
April 1, 2020
April 2020
Dear Colleagues,
We are living through extraordinary times, and I thank everyone for taking the steps necessary to stay healthy and care for family, friends and loved ones.
New York Times: How Are You Feeling? Surveys Aim to Detect Covid-19 Hot Spots Early
April 1, 2020
Scientists have persuaded Britons and Israelis to fill out questionnaires about their health, to get ahead of the coronavirus by getting resources to the right place. The U.S. is next.
EIPM Joins Very Rare Cancer Research Initiative
June 26, 2019
NEW YORK – When a patient turned up at the Weill Cornell Medical Center a few years ago with a typically benign kidney tumor type, it did not initially set off alarm bells. The tumor didn’t seem all that threatening, and the patient was an adult, albeit somewhat younger than individuals who usually come in with that kind of tumor.
A Conversation with Dr. M. Laura Martin
May 29, 2019
M. Laura Martin, Ph.D. was recently promoted to the Core Leadership Team at the Englander Institute for Precision Medicine (EIPM) as Ex Vivo Models Director. In this new capacity she will lead efforts in the utilization of patient derived models of cancer, studying the functional impact of genetic and epigenetic alterations in preclinical models, and investigating the potential to translate these findings to clinical relevance.
View EIPM’s National Cancer Research Month Video
May 21, 2019
In recognition of May’s designation as National Cancer Research Month, EIPM Director Olivier Elemento, Ph.D. shares his thoughts on the state of precision medicine in creating next-generation treatment for cancer. Please click here or on the link below to play the video.
EIPM Joins International Cancer Consortium
May 14, 2019
Weill Cornell Medicine’s Englander Institute for Precision Medicine (EIPM) recently joined the Human Cancer Models Initiative (HCMI) and will become one of four Cancer Model Development Centers (CMDCs) in the United States. EIPM is participating in this project through a subcontract with Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute.